ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011
NK cells, innate immunity and hepatitis C infection after liver transplantation.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis.Journal of clinical and translational hepatology · 2021Review
- Review
- Review
- Model of the adaptive immune response system against HCV infection reveals potential immunomodulatory agents for combination therapy.Scientific reports · 2018Article
- Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.PloS one · 2017Article
- Spontaneous and natural cytotoxicity receptor-mediated cytotoxicity are effector functions of distinct natural killer subsets in hepatitis C virus-infected chimpanzees.Clinical and experimental immunology · 2016Article
- Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.Digestive diseases and sciences · 2016Article
- The Microbiome, Systemic Immune Function, and Allotransplantation.Clinical microbiology reviews · 2016Review
- Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.World journal of hepatology · 2015Review
- Genetic variants of innate immune receptors and infections after liver transplantation.World journal of gastroenterology · 2014Review
- Hepatitis C virus impairs natural killer cell-mediated augmentation of complement synthesis.Journal of virology · 2014Article
- Contradictory immune response in post liver transplantation hepatitis B and C.International journal of inflammation · 2014Review
- Natural killer cell function and dysfunction in hepatitis C virus infection.BioMed research international · 2014Review
- Opportunistic infections--coming to the limits of immunosuppression?Cold Spring Harbor perspectives in medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Liver transplantation in patients with active hepatitis C virus (HCV) infection is followed by almost universal recurrence of viral infection. The control of HCV infection has been characterized largely in terms of the HCV-specific function of T-lymphocytes and the adaptive immune response. Emerging data suggest that components of the innate immune system, including natural killer cells, have a central role in determining the nature of posttransplant HCV infection and the likelihood of response to antiviral therapy. This review examines the emerging evidence implicating innate immunity in the pathogenesis of posttransplant HCV infections and the potential therapeutic implications of these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.